Angiotech retains neutral rating from Merrill

Merrill Lynch rated Angiotech Pharmaceutical as neutral after hearing news that the Angiotech's Taxus stent lost market share in the United States - 55% in the third quarter, down from 59% last quarter. In contrast, analyst Hari Sambasivam noted that international sales were stronger than projected, partly due to a strong launch of the second-generation Taxus-Liberté stent.

Shares of the Vancouver, B.C.-based pharmaceutical company were down $0.15, or 1.10%, at $13.49 on volume of 401,738 shares versus the three-month running average of 514,765 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.